• AdvanCell

  Participated · Series D · Jul 2026

  AdvanCell develops targeted alpha radiopharmaceutical therapies built around a proprietary Lead-212 platform that combines secure isotope supply, automated manufacturing and scalable production. Its lead program, ADVC001, is a Lead-212 PSMA-targeted alpha therapy for metastatic prostate cancer that has shown encouraging Phase 1b anti-tumor activity and favorable tolerability and is currently in Phase 2 clinical development. The company emphasizes vertical integration — spanning isotope supply, advanced manufacturing and clinical development — to address supply and manufacturing constraints for targeted alpha therapies. With integrated operations across North America and Australia, AdvanCell plans to expand U.S. manufacturing infrastructure to support Phase 3 development and future commercial demand. The recent US $315 million Series D financing is intended to advance ADVC001 toward registrational development and accelerate the company’s growing pipeline of targeted alpha therapies.

• Artios Pharma

  Participated · Series D · Nov 2025

  Artios Pharma is pioneering next-generation oncology medicines that exploit DNA damage response (DDR) mechanisms to selectively destroy hard-to-treat tumors. Its lead asset, the ATR inhibitor alnodesertib, has produced durable responses across eight solid tumor types, particularly in ATM-deficient cancers where no approved therapies currently exist. The company’s second clinical candidate, ART6043, is a DNA Polymerase θ inhibitor intended for BRCA-mutant, HER2-negative breast cancer patients eligible for PARP inhibitors, while additional pre-clinical programs include DDRi-antibody drug conjugates. Proceeds from the latest financing will broaden Phase 2 studies of alnodesertib in second-line pancreatic and third-line colorectal cancers—indications recently granted FDA Fast Track status—and will fund a randomized Phase 2 trial of ART6043. Management, led by newly appointed CEO Mike Andriole, believes these efforts will accelerate both assets toward registration. Following the $115 million Series D, the company is well-capitalized to advance its pipeline and transition toward commercial readiness.

• Kardium

  Led · Equity · Jul 2025

  Kardium developed the Globe® Pulsed Field System, a catheter-based AF treatment featuring a 122-electrode array for rapid pulmonary vein isolation, high-definition mapping, and whole‑atrium ablation with a single catheter. The Globe System showed 78% freedom from atrial arrhythmia at 1 year in paroxysmal AF patients in the pivotal PULSAR study and reported 0% device-related primary safety events. The system is currently restricted to investigational use and has not been approved or cleared for commercial distribution. Kardium plans to use new funding to pursue regulatory approvals, expand manufacturing and production capacity, build a clinical support and commercial team, and run further clinical research for additional applications and indications. The company is privately held, was founded in 2007, and is headquartered in Vancouver, Canada. The recent financing positions Kardium to move toward a commercial launch later this year. Kardium develops the Globe Mapping and Ablation System, a single-catheter solution with a 122-electrode array and advanced software for rapid pulmonary vein isolation, high-definition mapping, and atrial ablation. The company says recent clinical data show freedom from atrial arrhythmia at one year of 84.2% in paroxysmal AF and 80% in persistent AF. Kardium raised US $104 million in a new financing to support completion of its PULSAR clinical study and to pursue regulatory approvals for the Globe System. The financing will also fund growth of manufacturing capacity and expansion of clinical support and commercial teams in preparation for commercial launch. Kardium is a privately held company founded in 2007 and headquartered in Vancouver, Canada. The Globe System remains restricted to investigational use and has not been approved or cleared for commercial distribution. Kardium has developed the Globe Mapping and Ablation System for the treatment of atrial fibrillation. The Globe System uses a sophisticated catheter with a 122-electrode array and advanced software to enable rapid pulmonary vein isolation, high-definition mapping, and the ability to ablate anywhere in the atrium with a single catheter. In the past six months the company secured CE mark approval, launched the Globe System in Europe, and deployed the Globe Positioning System (GPS) 3D mapping and navigation module. The new financing will be used to accelerate commercial growth across Europe and to conduct a clinical study for FDA approval of the Globe System. The financing will also fund clinical studies of a new pulsed field ablation (PFA) version of the Globe System following positive pre-clinical testing. Founded in 2007 and headquartered in Vancouver, Kardium plans to expand activity across European markets and advance its FDA submissions. Kardium develops the Globe® Mapping and Ablation System, a mapping and ablation solution for the treatment of atrial fibrillation. The Globe system pairs a sophisticated catheter with 122 electrodes and advanced software to enable rapid pulmonary vein isolation, high-resolution mapping, and the ability to ablate anywhere in the atrium. Kardium completed successful clinical testing of the Globe system in Switzerland and Germany and plans commercial sales in Europe in 2019. The company will also start a clinical study in the US this year. Kardium was founded in 2007 and is based in Vancouver, British Columbia. It announced a new, undisclosed financing led by funds and accounts advised by T. Rowe Price, which the company said will fund commercial activities in Europe and Canada and support US clinical testing.

• Saluda Medical

  Participated · Equity · Jan 2025

  Saluda Medical develops a proprietary closed-loop, dose-control neuromodulation platform and is commercial-stage with its first product, the Evoke® System. The Evoke System is a physiologic closed-loop spinal cord stimulation (SCS) system that senses neural responses and automatically adjusts therapy to maintain a targeted level of neural activation. The system is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including failed back surgery syndrome, intractable low back pain, leg pain, and chronic neuropathic pain. Saluda cites randomized, multi-center pivotal-study results with 12-month data published in The Lancet Neurology, 24-month results in JAMA Neurology, and 36-month data in Regional Anesthesia and Pain Medicine. Net proceeds from the financing will be used primarily to advance commercialization of the Evoke System. The company is continuing commercial efforts from its Minneapolis base. Saluda Medical, based in Artarmon, Australia, advances a portfolio of therapies driven by advanced closed‑loop technologies for debilitating neurological disorders. Its first product is the Evoke SmartSCS System, an ECAP‑controlled closed‑loop spinal cord stimulation (SCS) system. The Evoke System is indicated as an aid in the management of chronic intractable trunk and/or limb pain, including pain associated with failed back surgery syndrome and intractable low back and leg pain. The device automatically reads, records, and responds to nerves’ responses to stimulation more than 4 million times a day to continually optimize therapy. The company states the Evoke System is proven to be superior to open‑loop SCS for treatment of overall trunk and/or limb pain. Saluda is led by President and CEO Jim Schuermann and is advancing its technology platform alongside commercial plans for Evoke. Saluda Medical is a medical device company developing the Evoke® ECAP-Controlled, Closed-Loop Spinal Cord Stimulation (SCS) System to treat chronic intractable pain of the trunk and limbs. The Evoke system measures the spinal cord’s response to stimulation via evoked compound action potentials (ECAPs) and adjusts on every pulse to maintain activation within a patient’s therapeutic window. Saluda is advancing Evoke through the first double-blinded, randomized, controlled U.S. pivotal study and is pursuing regulatory approval to market the system. The company intends to use newly raised capital to fund final development stages through commercialization. Saluda is led by CEO John Parker and has offices in Artarmon, Australia; Bloomington, Minnesota; and Harrogate, UK. Saluda Medical Pty Limited is a medical device company developing a platform of closed-loop neuromodulation technologies based on neural response to stimulation. The platform is built to sense neural responses and adapt stimulation accordingly. The company is based in Australia. Saluda secured A$53 million (US$40 million) in an all-equity financing round. That financing was reported as a Series D led by Action Potential VC. Saluda Medical is a Sidney, Australia-based provider of technology and devices to treat chronic pain and other conditions. The company develops Evoke™, a spinal cord stimulation system designed to treat chronic pain of the trunk and limbs. Its neuromodulation technology measures nerve signals and adjusts stimulation in real time. Saluda is exploring applications of its platform for Parkinson's disease, epilepsy and other debilitating disorders. The company plans to use recently raised funds to conduct chronic clinical trials and support commercialization of Evoke. Saluda is a spin-out from NICTA and is led by CEO John Parker.

• Alentis Therapeutics

  Participated · Series D · Nov 2024

  Alentis Therapeutics is a clinical-stage company pioneering anti-CLDN1 antibody-drug conjugates (ADCs) and antibodies to treat CLDN1+ tumors and fibrotic disease. Its lead programs, ALE.P02 (tubulin inhibitor payload) and ALE.P03 (topoisomerase I inhibitor payload), are first-in-class ADCs designed to target a unique CLDN1 epitope on cancer cells. The company plans Phase 1/2 clinical studies for ALE.P02 and ALE.P03, with an IND for ALE.P02 recently cleared by the FDA. ALE.P02’s Phase 1/2 trial is expected to commence in Q1 2025, and a first-in-human trial for ALE.P03 is planned in 2025. Alentis was founded on research from Prof. Thomas Baumert’s lab and maintains headquarters in Basel, Switzerland with R&D in Strasbourg and clinical operations in the U.S. The company says its CLDN1 programs aim to deliver potent anti-cancer activity with reduced toxicity compared with traditional chemotherapies. Alentis Therapeutics is a clinical-stage biotech focused on developing breakthrough treatments that target Claudin‑1 (CLDN1) for organ fibrosis and CLDN1‑positive solid tumors. Its lead investigational products are ALE.F02 and ALE.C04, with ALE.F02 nearing completion of its MAD study and ALE.C04 being developed for CLDN1+ oncology populations including T‑cell excluded cancers. Alentis has built a CLDN1 platform to engineer antibody‑drug conjugates (ADCs) and bi‑specific antibodies and is advancing that platform alongside its clinical programs. The company plans to use new funding to support a Phase II program for ALE.F02, a Phase I program for ALE.C04, continue recruitment for organ fibrosis trials, and further develop its ADC and bi‑specific programs. Alentis was founded in 2019 and is headquartered in Basel, Switzerland, with an R&D subsidiary in Strasbourg, France and clinical operations in the US. Financially, the company has raised a $105 million Series C following a $67 million Series B in June 2021 to accelerate clinical development and platform advancement. Alentis Therapeutics is developing first‑in‑class, Claudin‑1‑targeting monoclonal antibodies (lead candidates ALE.F02 and ALE.C04) to treat liver, kidney and other organ fibrosis and fibrosis-driven hepatobiliary cancers. Preclinical studies showed ALE.F02 can modulate non-junctional Claudin‑1 to prevent and possibly reverse fibrotic tissue growth, and safety studies in non-human primates supported translatability to patients. The company uses a patient-derived drug and target discovery platform and has early discovery programs exploring Claudin‑1 inhibition in kidney and lung fibrosis. Alentis plans to use the Series B proceeds primarily to fund proof‑of‑concept clinical trials in advanced liver and kidney fibrosis and to support ongoing drug discovery programs and oncology indications. The company expects to initiate its first clinical trial in Q4 2021. Alentis was founded in 2019 based on research from Prof. Thomas Baumert's laboratory, is headquartered in Basel with an R&D subsidiary in Strasbourg, and recently completed a $67M (CHF60M) Series B. Alentis Therapeutics is developing novel therapeutics focused on advanced liver disease and hepatocellular carcinoma. The company is advancing a humanized monoclonal antibody against a target implicated in liver fibrosis and HCC. Its research is powered by a proprietary drug discovery platform based on a prognostic liver disease signature, which the company says holds promise for discovering additional drug candidates. Alentis was founded on research from the laboratory of Prof. Thomas Baumert at the University of Strasbourg and collaborators including Prof. Yujin Hoshida at UT Southwestern. The company is headquartered in Basel and maintains a subsidiary in Strasbourg and a branch in Germany. It recently completed a Series A financing and announced a new CEO, Markus L.E. Ewert.

No current team members are available.